Enterprise Integration Onc.AI’s clinically validated imaging AI targets first line immune checkpoint inhibitor planning, offering a strong case for integration with hospital PACS and EMR systems to deliver a seamless clinical decision support workflow. The FDA breakthrough designation and radiomic biomarker capability can help de-risk adoption and show hospital ROI through improved treatment alignment.

Pharma Collaboration The 2025 Series A funding and collaboration with GSK position Onc.AI as a partner for pharma in biomarker development, trial stratification, and companion diagnostic workups. A licensing or co-development model could monetize AI insights across clinical trials and accelerate immunotherapy programs.

Channel Partnerships Given the lean team size, a channel partner approach with CROs, imaging centers, and health IT integrators can scale deployment faster than direct sales. A formal partner program with joint marketing, training, and revenue sharing could unlock hospital and lab access across North America and beyond.

Market Expansion With US headquarters and major conference activity at ASCO and AACR, Onc.AI is primed for regional expansion through existing relationships and early adopters. Focus on North American cancer centers initially, then extend to Europe and Canada using partner networks and reference sites from ongoing collaborations.

Data Driven Differentiation Radiomic based AI with clinical performance data provides a compelling differentiator for payers and hospitals seeking outcome-based value. Build and communicate real world evidence and survival prediction results to support reimbursement discussions and broaden adoption through data licensing and research collaborations.